VEGFR2/CD309 anticorps (N-Term)

N° du produit ABIN926995

Cet anticorps Lapin Polyclonal détecte spécifiquement VEGFR2/CD309 dans WB et IHC. Il présente une réactivité envers Humain et Chien.

Aperçu rapide pour VEGFR2/CD309 anticorps (N-Term) (ABIN926995)

Antigène: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Reactivité: Humain, Chien

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp VEGFR2/CD309 est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (IHC)

Détail du produit anti-VEGFR2/CD309 anticorps

Épitope: N-Term

Réactivité croisée: Chien

Purification: Purified

Immunogène: KDR antibody was raised in rabbit using the N terminal of KDR as the immunogen

Information d'application

Indications d'application: WB: 0.2-1 µg/mL
Optimal conditions should be determined by the investigator.

Commentaires:

KDR Blocking Peptide, , is also available for use as a blocking control in assays to test for specificity of this KDR antibody

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Concentration: Lot specific

Buffer: Lyophilized powder. Add 50 µL of distilled water. Final antibody concentration is 1 mg/mL in PBS buffer.

Conseil sur la manipulation: Avoid repeated freeze/thaw cycles.

Stock: 4 °C/-20 °C

Stockage commentaire: Store at 4 °C, following reconstitution, aliquot and store at -20 °C.

Détails sur VEGFR2/CD309

Antigène: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Autre désignation: KDR

Sujet: KDR is the receptor for VEGF or VEGFC. It has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions. Synonyms: Polyclonal KDR antibody, Anti-KDR antibody, kinase insert domain receptor, a type III receptor tyrosine kinase antibody, CD309 antibody, FLK1 antibody, VEGFR antibody, VEGFR2 antibody.

Pathways: Signalisation RTK, Glycosaminoglycan Metabolic Process, Signaling Events mediated by VEGFR1 and VEGFR2, Growth Factor Binding, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling